About the Company
Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CNAT News
Kathleen D. Scott's Net Worth
Who is Kathleen D. Scott? Kathleen D. Scott does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which ...
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton ...
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Todd Foley's Net Worth
Todd Foley has an estimated net worth of $598 Million. This is based on reported shares across multiple companies, which include RHYTHM PHARMACEUTICALS, INC., iTeos Therapeutics, Inc., TriVascular ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
BioCryst Pharmaceuticals, Inc. (BCRX)
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024. On May 13, 2024, Steven Galson ...
Histogen Inc. Common Stock (HSTO)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
RIGL Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...
Supernus Pharmaceuticals Inc SUPN
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
ALNY Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products ...
Loading the latest forecasts...